Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 504
- Registration Number
- NCT02611700
- Locations
- 🇨🇳
Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, Beijing, China
🇨🇳Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳AnHui Provincial Hospital, Hefei, Anhui, China
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02591784
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The Affiliated tumour hosiptal of HARBIN Medical University, Harbin, Heilongjiang, China
🇨🇳Qilu Hospital,Shandong University, Jinan, Shandong, China
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 122
- Registration Number
- NCT02577341
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02549261
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT02428764
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 200
- Registration Number
- NCT02409186
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
🇨🇳Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02395068
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT02395016
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT02370849
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Peking University
- Registration Number
- NCT02272699
- Locations
- 🇨🇳
Beijing Cancer Hospital & Peking University Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.